Abstract | OBJECTIVES: METHODS: This multicentre, randomized, double-blind, comparator-controlled, Phase 2 study (protocol MK0991-064; NCT01945281) enrolled participants <3 months of age with culture-confirmed ICI within 96 h of study entry. Participants were randomly assigned 2:1 to once-daily intravenous 2 mg/kg caspofungin or intravenous 1 mg/kg amphotericin B deoxycholate (dAMB). The primary endpoint was fungal-free survival (FFS) 2 weeks after treatment in the full-analysis-set (FAS) population, defined as participants with culture-confirmed ICI who received ≥1 dose of therapy. Planned enrolment was 90 participants. RESULTS: Fifty-one participants were enrolled; 49 received treatment ( caspofungin, n=33; dAMB, n=16); 2 additional participants did not have confirmed infections at study entry. The study was terminated after ∼ 3.5 years because of low enrolment. Forty-seven participants were included in the FAS population ( caspofungin, n=31; dAMB, n=16). FFS rate at 2 weeks after treatment was 71.0% (22/31) in the caspofungin arm and 68.8% (11/16) in the dAMB arm [difference, stratified by weight, - 0.9% (95% CI, - 24.3%-27.7%)]. Adverse events developed in 84.8% (28/33) of participants in the caspofungin arm and 100% (16/16) in the dAMB arm. CONCLUSIONS: Among neonates and infants with confirmed ICI, FFS at 2 weeks was similar in the caspofungin and dAMB treatment arms. A smaller proportion of participants who received caspofungin experienced adverse events.
|
Authors | Jason Kim, Firdose Lambey Nakwa, Fábio Araujo Motta, Hong Liu, Mary Beth Dorr, Leah J Anderson, Nicholas Kartsonis |
Journal | The Journal of antimicrobial chemotherapy
(J Antimicrob Chemother)
Vol. 75
Issue 1
Pg. 215-220
(01 01 2020)
ISSN: 1460-2091 [Electronic] England |
PMID | 31586424
(Publication Type: Clinical Trial, Phase II, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © The Author(s) 2019. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email: [email protected]. |
Chemical References |
- Antifungal Agents
- Drug Combinations
- Deoxycholic Acid
- Amphotericin B
- amphotericin B, deoxycholate drug combination
- Caspofungin
|
Topics |
- Amphotericin B
(therapeutic use)
- Antifungal Agents
(therapeutic use)
- Candidiasis, Invasive
(drug therapy)
- Caspofungin
(therapeutic use)
- Deoxycholic Acid
(therapeutic use)
- Double-Blind Method
- Drug Combinations
- Female
- Humans
- Infant
- Infant, Newborn
- Male
- Treatment Outcome
|